Suchen
Cardio Diagnostics Holdings Inc
CDIOZur Watchlist hinzufügen
1.990USD
-0.120-5.69%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
3.52MMarktkapitalisierung
0.08KGV TTM
mehr Informationen über Cardio Diagnostics Holdings Inc Unternehmen
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Cardio Diagnostics Holdings Inc Informationen
BörsenkürzelCDIO
Name des UnternehmensCardio Diagnostics Holdings Inc
IPO-datumNov 23, 2021
CEODogan (Meeshanthini V)
Anzahl der mitarbeiter13
WertpapierartOrdinary Share
GeschäftsjahresendeNov 23
Addresse311 W. Superior Street
StadtCHICAGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl60645
Telefon18552269991
Website
BörsenkürzelCDIO
IPO-datumNov 23, 2021
CEODogan (Meeshanthini V)
Führungskräfte von Cardio Diagnostics Holdings Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Timur Dogan, Ph.D.
Mr. Timur Dogan, Ph.D.
Chief Technology Officer
Chief Technology Officer
107.26K
+96.01%
Dr. Warren Hosseinion, M.D.
Dr. Warren Hosseinion, M.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
3.87K
--
Dr. Robert Philibert, M.D., Ph.D.
Dr. Robert Philibert, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
3.25K
--
Mr. James Intrater
Mr. James Intrater
Independent Director
Independent Director
2.39K
--
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Elisa Luqman, Esq., J.D.
Ms. Elisa Luqman, Esq., J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul F. Burton, J.D.
Mr. Paul F. Burton, J.D.
Independent Director
Independent Director
--
--
Ms. Wendy J. Betts
Ms. Wendy J. Betts
Independent Director
Independent Director
--
--
Mr. Peter K. Fung
Mr. Peter K. Fung
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Timur Dogan, Ph.D.
Mr. Timur Dogan, Ph.D.
Chief Technology Officer
Chief Technology Officer
107.26K
+96.01%
Dr. Warren Hosseinion, M.D.
Dr. Warren Hosseinion, M.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
3.87K
--
Dr. Robert Philibert, M.D., Ph.D.
Dr. Robert Philibert, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
3.25K
--
Mr. James Intrater
Mr. James Intrater
Independent Director
Independent Director
2.39K
--
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Dr. Meeshanthini V. (Meesha) Dogan, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Elisa Luqman, Esq., J.D.
Ms. Elisa Luqman, Esq., J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Cardio Diagnostics Holdings Inc?
Die fünf größten Anteilseigner von Cardio Diagnostics Holdings Inc sind: Mr. Timur Dogan, Ph.D.
Wie viele Institutionen halten Anteile an Cardio Diagnostics Holdings Inc (CDIO)?
Mit Stand vom 2026Q1 halten 38 Institutionen Anteile an Cardio Diagnostics Holdings Inc, mit einem Gesamtmarktwert von etwa 138.49K, was 4.68% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -23968.00 gestiegen.